Robeco Schweiz AG Cuts Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Robeco Schweiz AG trimmed its position in shares of Boston Scientific Co. (NYSE:BSX) by 27.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 268,508 shares of the medical equipment provider’s stock after selling 102,568 shares during the quarter. Robeco Schweiz AG’s holdings in Boston Scientific were worth $15,522,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently bought and sold shares of the company. Bruce G. Allen Investments LLC bought a new stake in shares of Boston Scientific during the 4th quarter worth $28,000. Frazier Financial Advisors LLC bought a new stake in shares of Boston Scientific during the 4th quarter worth $32,000. Sachetta LLC bought a new stake in shares of Boston Scientific during the 4th quarter worth $32,000. Jones Financial Companies Lllp raised its stake in shares of Boston Scientific by 53.0% during the 4th quarter. Jones Financial Companies Lllp now owns 557 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 193 shares during the period. Finally, Venturi Wealth Management LLC raised its stake in shares of Boston Scientific by 58.0% during the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 215 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Boston Scientific news, EVP John Bradley Sorenson sold 16,351 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $69.30, for a total value of $1,133,124.30. Following the completion of the transaction, the executive vice president now owns 50,638 shares in the company, valued at $3,509,213.40. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, EVP John Bradley Sorenson sold 16,351 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $69.30, for a total value of $1,133,124.30. Following the sale, the executive vice president now directly owns 50,638 shares of the company’s stock, valued at $3,509,213.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $75.33, for a total value of $526,029.39. Following the sale, the executive vice president now directly owns 45,628 shares in the company, valued at $3,437,157.24. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 81,627 shares of company stock worth $5,937,353. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Trading Down 0.3 %

Shares of Boston Scientific stock traded down $0.22 during midday trading on Tuesday, reaching $77.20. 141,184 shares of the company’s stock traded hands, compared to its average volume of 6,324,944. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66. The company has a market cap of $113.26 billion, a PE ratio of 65.07, a price-to-earnings-growth ratio of 2.65 and a beta of 0.81. The stock has a 50 day moving average of $72.36 and a 200-day moving average of $65.55. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $77.56.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.51 by $0.05. The business had revenue of $3.86 billion during the quarter, compared to the consensus estimate of $3.68 billion. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. As a group, equities analysts expect that Boston Scientific Co. will post 2.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BSX. UBS Group lifted their target price on Boston Scientific from $74.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Royal Bank of Canada boosted their price objective on Boston Scientific from $78.00 to $82.00 and gave the company an “outperform” rating in a research note on Thursday, April 25th. Evercore ISI boosted their price objective on Boston Scientific from $72.00 to $78.00 and gave the company an “outperform” rating in a research note on Thursday, April 25th. Barclays lifted their target price on Boston Scientific from $70.00 to $78.00 and gave the company an “overweight” rating in a report on Friday, April 26th. Finally, StockNews.com raised Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday. Two investment analysts have rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $76.70.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.